Literature DB >> 3577484

Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients.

E Asbrink, A Hovmark, I Olsson.   

Abstract

A study was made of 50 consecutive patients with untreated acrodermatitis chronica atrophicans (ACA). In all patients elevated anti-spirochetal antibody titers were found at indirect immunofluorescence and enzyme-linked immunosorbent assays, and histologically biopsies exhibited a dermal lymphocytic infiltrate with a moderate to rich admixture of plasma cells and telangiectases. Nine patients had a history consistent with spontaneously healing erythema chronicum migrans Afzelius (ECMA) on the extremity on which, after 0.5-8 years, ACA lesions developed. Eight patients had a history indicating previous cranial nerve involvement and nine had had periods of severe pains in the cervical or lumbar region. Two patients had developed ECMA, facial palsy and ACA in chronological order. In 15 patients radiographic abnormalities of joints and/or bone tissue were found. Besides ACA lesions, lichen sclerosus et atrophicus- or scleroderma-like lesions were found in six patients. The inflammatory ACA lesions were sometimes discrete and had been overlooked. Joint deformities, sclerotic lesions, diffuse edema or pain were the cardinal symptoms in some patients. The findings indicate that clinical recognition of ACA may be difficult and that a combination of clinical, histopathologic and serologic findings may be necessary to establish the diagnosis. The results are consistent with the concept that ACA is a late manifestation of infection by the same spirochete as causes ECMA and Bannwarth's syndrome.

Entities:  

Mesh:

Year:  1986        PMID: 3577484     DOI: 10.1016/s0176-6724(86)80128-6

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  12 in total

1.  Two unusual cases of diffuse acrodermatitis chronica atrophicans seronegative for Lyme borreliosis.

Authors:  T G Berger; C Schoerner; H Schell; M Simon; G Schuler; M Röllinghoff; A Gessner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-29       Impact factor: 3.267

Review 2.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

3.  Asymmetric red-bluish foot due to acrodermatitis chronica atrophicans.

Authors:  Anh Ly Nguyen; Wim J A de Kort; Chantal C W Theunissen
Journal:  BMJ Case Rep       Date:  2016-06-22

Review 4.  Challenges in the Diagnosis and Treatment of Lyme Disease.

Authors:  Robert T Schoen
Journal:  Curr Rheumatol Rep       Date:  2020-01-07       Impact factor: 4.592

Review 5.  Morphoea and Borrelia burgdorferi: results from the Scottish Highlands in the context of the world literature.

Authors:  J R Goodlad; M M Davidson; P Gordon; R Billington; D O Ho-Yen
Journal:  Mol Pathol       Date:  2002-12

6.  Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis.

Authors:  H Kuiper; A P van Dam; L Spanjaard; B M de Jongh; A Widjojokusumo; T C Ramselaar; I Cairo; K Vos; J Dankert
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

7.  Characterization of Finnish Borrelia burgdorferi sensu lato isolates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and with monoclonal antibodies.

Authors:  J Tuomi; L K Rantamäki; R Tanskanen; J Junttila
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis.

Authors:  B Wilske; V Preac-Mursic; U B Göbel; B Graf; S Jauris; E Soutschek; E Schwab; G Zumstein
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

9.  Lyme borreliosis and cranial neuropathy.

Authors:  E Kindstrand
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

10.  Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis.

Authors:  S Hammers-Berggren; A M Lebech; M Karlsson; B Svenungsson; K Hansen; G Stiernstedt
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.